Logo image of CLBT

CELLEBRITE DI LTD (CLBT) Stock Fundamental Analysis

USA - NASDAQ:CLBT - IL0011794802 - Common Stock

18.5 USD
-0.16 (-0.86%)
Last: 10/27/2025, 8:10:53 PM
18.87 USD
+0.37 (+2%)
After Hours: 10/27/2025, 8:10:53 PM
Fundamental Rating

5

Overall CLBT gets a fundamental rating of 5 out of 10. We evaluated CLBT against 285 industry peers in the Software industry. CLBT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. While showing a medium growth rate, CLBT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

CLBT had positive earnings in the past year.
CLBT had a positive operating cash flow in the past year.
In multiple years CLBT reported negative net income over the last 5 years.
In the past 5 years CLBT always reported a positive cash flow from operatings.
CLBT Yearly Net Income VS EBIT VS OCF VS FCFCLBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of CLBT (-19.17%) is worse than 70.88% of its industry peers.
CLBT has a worse Return On Equity (-36.96%) than 63.86% of its industry peers.
CLBT has a Return On Invested Capital of 10.23%. This is amongst the best in the industry. CLBT outperforms 86.32% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CLBT is below the industry average of 11.88%.
The last Return On Invested Capital (10.23%) for CLBT is above the 3 year average (7.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -19.17%
ROE -36.96%
ROIC 10.23%
ROA(3y)-9.14%
ROA(5y)-1.85%
ROE(3y)-54.72%
ROE(5y)N/A
ROIC(3y)7.06%
ROIC(5y)7.59%
CLBT Yearly ROA, ROE, ROICCLBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

With an excellent Operating Margin value of 14.16%, CLBT belongs to the best of the industry, outperforming 80.35% of the companies in the same industry.
In the last couple of years the Operating Margin of CLBT has grown nicely.
CLBT has a Gross Margin of 84.38%. This is amongst the best in the industry. CLBT outperforms 91.93% of its industry peers.
CLBT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.16%
PM (TTM) N/A
GM 84.38%
OM growth 3Y10.9%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.66%
GM growth 5Y1.3%
CLBT Yearly Profit, Operating, Gross MarginsCLBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

7

2. Health

2.1 Basic Checks

CLBT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
CLBT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLBT has been increased compared to 5 years ago.
CLBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLBT Yearly Shares OutstandingCLBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CLBT Yearly Total Debt VS Total AssetsCLBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CLBT has an Altman-Z score of 8.26. This indicates that CLBT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CLBT (8.26) is better than 78.60% of its industry peers.
There is no outstanding debt for CLBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.26
ROIC/WACC1.11
WACC9.22%
CLBT Yearly LT Debt VS Equity VS FCFCLBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.96 indicates that CLBT should not have too much problems paying its short term obligations.
The Current ratio of CLBT (1.96) is comparable to the rest of the industry.
CLBT has a Quick Ratio of 1.92. This is a normal value and indicates that CLBT is financially healthy and should not expect problems in meeting its short term obligations.
CLBT's Quick ratio of 1.92 is in line compared to the rest of the industry. CLBT outperforms 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.92
CLBT Yearly Current Assets VS Current LiabilitesCLBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.75% over the past year.
Looking at the last year, CLBT shows a very strong growth in Revenue. The Revenue has grown by 20.48%.
CLBT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.47% yearly.
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)20.48%
Revenue growth 3Y17.68%
Revenue growth 5Y18.47%
Sales Q2Q%18.35%

3.2 Future

Based on estimates for the next years, CLBT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.94% on average per year.
The Revenue is expected to grow by 15.18% on average over the next years. This is quite good.
EPS Next Y18.9%
EPS Next 2Y12.72%
EPS Next 3Y12.96%
EPS Next 5Y12.94%
Revenue Next Year17.63%
Revenue Next 2Y17.21%
Revenue Next 3Y17.04%
Revenue Next 5Y15.18%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CLBT Yearly Revenue VS EstimatesCLBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
CLBT Yearly EPS VS EstimatesCLBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0.2 0.4 0.6

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 40.22, which means the current valuation is very expensive for CLBT.
60.70% of the companies in the same industry are more expensive than CLBT, based on the Price/Earnings ratio.
CLBT is valuated rather expensively when we compare the Price/Earnings ratio to 27.08, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 34.67, CLBT can be considered very expensive at the moment.
CLBT's Price/Forward Earnings ratio is in line with the industry average.
CLBT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.09.
Industry RankSector Rank
PE 40.22
Fwd PE 34.67
CLBT Price Earnings VS Forward Price EarningsCLBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CLBT indicates a somewhat cheap valuation: CLBT is cheaper than 64.21% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CLBT is valued a bit cheaper than 72.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF 30.35
EV/EBITDA 52.42
CLBT Per share dataCLBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CLBT does not grow enough to justify the current Price/Earnings ratio.
CLBT's earnings are expected to grow with 12.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.13
PEG (5Y)N/A
EPS Next 2Y12.72%
EPS Next 3Y12.96%

0

5. Dividend

5.1 Amount

CLBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CELLEBRITE DI LTD

NASDAQ:CLBT (10/27/2025, 8:10:53 PM)

After market: 18.87 +0.37 (+2%)

18.5

-0.16 (-0.86%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners44.23%
Inst Owner Change-0.22%
Ins Owners2.65%
Ins Owner ChangeN/A
Market Cap4.52B
Revenue(TTM)436.73M
Net Income(TTM)-150948000
Analysts84.29
Price Target24.14 (30.49%)
Short Float %5.83%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.37%
Min EPS beat(2)12.81%
Max EPS beat(2)15.93%
EPS beat(4)4
Avg EPS beat(4)21.79%
Min EPS beat(4)0.93%
Max EPS beat(4)57.51%
EPS beat(8)8
Avg EPS beat(8)51.82%
EPS beat(12)11
Avg EPS beat(12)53.22%
EPS beat(16)13
Avg EPS beat(16)50.32%
Revenue beat(2)0
Avg Revenue beat(2)-2.3%
Min Revenue beat(2)-3.58%
Max Revenue beat(2)-1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.52%
Min Revenue beat(4)-3.58%
Max Revenue beat(4)2.78%
Revenue beat(8)5
Avg Revenue beat(8)0.93%
Revenue beat(12)7
Avg Revenue beat(12)0.54%
Revenue beat(16)9
Avg Revenue beat(16)0.41%
PT rev (1m)2.9%
PT rev (3m)-5.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0%
EPS NY rev (3m)6.69%
Revenue NQ rev (1m)-0.31%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-1.09%
Valuation
Industry RankSector Rank
PE 40.22
Fwd PE 34.67
P/S 10.36
P/FCF 30.35
P/OCF 28.08
P/B 11.07
P/tB 12.24
EV/EBITDA 52.42
EPS(TTM)0.46
EY2.49%
EPS(NY)0.53
Fwd EY2.88%
FCF(TTM)0.61
FCFY3.29%
OCF(TTM)0.66
OCFY3.56%
SpS1.79
BVpS1.67
TBVpS1.51
PEG (NY)2.13
PEG (5Y)N/A
Graham Number4.16
Profitability
Industry RankSector Rank
ROA -19.17%
ROE -36.96%
ROCE 12.96%
ROIC 10.23%
ROICexc 926.92%
ROICexgc N/A
OM 14.16%
PM (TTM) N/A
GM 84.38%
FCFM 34.12%
ROA(3y)-9.14%
ROA(5y)-1.85%
ROE(3y)-54.72%
ROE(5y)N/A
ROIC(3y)7.06%
ROIC(5y)7.59%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.94%
ROCE(5y)9.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y10.9%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.66%
GM growth 5Y1.3%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 114.28%
Cap/Sales 2.77%
Interest Coverage 250
Cash Conversion 222.39%
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.92
Altman-Z 8.26
F-Score5
WACC9.22%
ROIC/WACC1.11
Cap/Depr(3y)92.67%
Cap/Depr(5y)99.76%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y18.9%
EPS Next 2Y12.72%
EPS Next 3Y12.96%
EPS Next 5Y12.94%
Revenue 1Y (TTM)20.48%
Revenue growth 3Y17.68%
Revenue growth 5Y18.47%
Sales Q2Q%18.35%
Revenue Next Year17.63%
Revenue Next 2Y17.21%
Revenue Next 3Y17.04%
Revenue Next 5Y15.18%
EBIT growth 1Y23.19%
EBIT growth 3Y30.51%
EBIT growth 5YN/A
EBIT Next Year32.85%
EBIT Next 3Y23.1%
EBIT Next 5Y19.13%
FCF growth 1Y160.75%
FCF growth 3Y63.25%
FCF growth 5Y65.07%
OCF growth 1Y150.74%
OCF growth 3Y54.2%
OCF growth 5Y52.3%

CELLEBRITE DI LTD / CLBT FAQ

What is the fundamental rating for CLBT stock?

ChartMill assigns a fundamental rating of 5 / 10 to CLBT.


Can you provide the valuation status for CELLEBRITE DI LTD?

ChartMill assigns a valuation rating of 3 / 10 to CELLEBRITE DI LTD (CLBT). This can be considered as Overvalued.


What is the profitability of CLBT stock?

CELLEBRITE DI LTD (CLBT) has a profitability rating of 5 / 10.


What are the PE and PB ratios of CELLEBRITE DI LTD (CLBT) stock?

The Price/Earnings (PE) ratio for CELLEBRITE DI LTD (CLBT) is 40.22 and the Price/Book (PB) ratio is 11.07.


Can you provide the financial health for CLBT stock?

The financial health rating of CELLEBRITE DI LTD (CLBT) is 7 / 10.